184 related articles for article (PubMed ID: 33554762)
41. Design, synthesis, and biological and crystallographic evaluation of novel inhibitors of Plasmodium falciparum enoyl-ACP-reductase (PfFabI).
Belluti F; Perozzo R; Lauciello L; Colizzi F; Kostrewa D; Bisi A; Gobbi S; Rampa A; Bolognesi ML; Recanatini M; Brun R; Scapozza L; Cavalli A
J Med Chem; 2013 Oct; 56(19):7516-26. PubMed ID: 24063369
[TBL] [Abstract][Full Text] [Related]
42. Oplodiol and nitidine as potential inhibitors of
Akakpo L; Gasu EN; Mensah JO; Borquaye LS
J Biomol Struct Dyn; 2024; 42(4):1655-1669. PubMed ID: 37194452
[TBL] [Abstract][Full Text] [Related]
43. Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase.
Perozzo R; Kuo M; Sidhu Ab; Valiyaveettil JT; Bittman R; Jacobs WR; Fidock DA; Sacchettini JC
J Biol Chem; 2002 Apr; 277(15):13106-14. PubMed ID: 11792710
[TBL] [Abstract][Full Text] [Related]
44. High-throughput virtual screening approach of natural compounds as target inhibitors of plasmepsin-II.
En-Nahli F; Baammi S; Hajji H; Alaqarbeh M; Lakhlifi T; Bouachrine M
J Biomol Struct Dyn; 2023 Nov; 41(19):10070-10080. PubMed ID: 36469727
[TBL] [Abstract][Full Text] [Related]
45. Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data.
Kuo MR; Morbidoni HR; Alland D; Sneddon SF; Gourlie BB; Staveski MM; Leonard M; Gregory JS; Janjigian AD; Yee C; Musser JM; Kreiswirth B; Iwamoto H; Perozzo R; Jacobs WR; Sacchettini JC; Fidock DA
J Biol Chem; 2003 Jun; 278(23):20851-9. PubMed ID: 12606558
[TBL] [Abstract][Full Text] [Related]
46. Identification of novel Plasmodium falciparum PI4KB inhibitors as potential anti-malarial drugs: Homology modeling, molecular docking and molecular dynamics simulations.
Ibrahim MAA; Abdelrahman AHM; Hassan AMA
Comput Biol Chem; 2019 Jun; 80():79-89. PubMed ID: 30928871
[TBL] [Abstract][Full Text] [Related]
47. Targeting metacaspase-3 from
Kumar B; Mohammad T; Amaduddin ; Hussain A; Islam A; Ahmad F; Alajmi MF; Singh S; Pandey KC; Hassan MI; Abid M
J Biomol Struct Dyn; 2021 Feb; 39(2):421-430. PubMed ID: 31900062
[TBL] [Abstract][Full Text] [Related]
48. In silico prediction and in vitro assessment of novel heterocyclics with antimalarial activity.
Orozco MI; Moreno P; Guevara M; Abonia R; Quiroga J; Insuasty B; Barreto M; Burbano ME; Crespo-Ortiz MDP
Parasitol Res; 2023 Dec; 123(1):75. PubMed ID: 38155300
[TBL] [Abstract][Full Text] [Related]
49. Exploring Novel Antimalarial Compounds Targeting
A R Oliveira G; G D V Morales B; M O Sousa R; S Pereira S; Antunes D; Caffarena ER; Zanchi FB
ACS Omega; 2024 May; 9(21):22777-22793. PubMed ID: 38826533
[TBL] [Abstract][Full Text] [Related]
50.
Ji X; Wang Z; Chen Q; Li J; Wang H; Wang Z; Yang L
Molecules; 2022 Apr; 27(9):. PubMed ID: 35566023
[TBL] [Abstract][Full Text] [Related]
51. In vitro dual activity of Aloe marlothii roots and its chemical constituents against Plasmodium falciparum asexual and sexual stage parasites.
Mianda SM; Invernizzi L; van der Watt ME; Reader J; Moyo P; Birkholtz LM; Maharaj VJ
J Ethnopharmacol; 2022 Oct; 297():115551. PubMed ID: 35850311
[TBL] [Abstract][Full Text] [Related]
52. Analysis of Enoyl-Acyl Carrier Protein Reductase Structure and Interactions Yields an Efficient Virtual Screening Approach and Suggests a Potential Allosteric Site.
Ghattas MA; Mansour RA; Atatreh N; Bryce RA
Chem Biol Drug Des; 2016 Jan; 87(1):131-42. PubMed ID: 26259619
[TBL] [Abstract][Full Text] [Related]
53. Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4'-substituted triclosan derivatives.
Freundlich JS; Anderson JW; Sarantakis D; Shieh HM; Yu M; Valderramos JC; Lucumi E; Kuo M; Jacobs WR; Fidock DA; Schiehser GA; Jacobus DP; Sacchettini JC
Bioorg Med Chem Lett; 2005 Dec; 15(23):5247-52. PubMed ID: 16198563
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of Antiplasmodial Potential of C2 and C8 Modified Quinolines: in vitro and in silico Study.
Kumar R; Sharma R; Kumar I; Upadhyay P; Dhiman AK; Kumar R; Kumar R; Purohit R; Sahal D; Sharma U
Med Chem; 2019; 15(7):790-800. PubMed ID: 30324888
[TBL] [Abstract][Full Text] [Related]
55. Natural products for treatment of Plasmodium falciparum malaria: An integrated computational approach.
Muhseen ZT; Hameed AR; Al-Bhadly O; Ahmad S; Li G
Comput Biol Med; 2021 Jul; 134():104415. PubMed ID: 33910128
[TBL] [Abstract][Full Text] [Related]
56. Pharmacophore-based virtual screening and molecular docking to identify promising dual inhibitors of human acetylcholinesterase and butyrylcholinesterase.
Mascarenhas AMS; de Almeida RBM; de Araujo Neto MF; Mendes GO; da Cruz JN; Dos Santos CBR; Botura MB; Leite FHA
J Biomol Struct Dyn; 2021 Oct; 39(16):6021-6030. PubMed ID: 32705955
[TBL] [Abstract][Full Text] [Related]
57. Targeting malaria with specific CDK inhibitors.
Geyer JA; Prigge ST; Waters NC
Biochim Biophys Acta; 2005 Dec; 1754(1-2):160-70. PubMed ID: 16185941
[TBL] [Abstract][Full Text] [Related]
58. Identification of the natural compound inhibitors against
Manhas A; Kumar S; Jha PC
J Biomol Struct Dyn; 2022 Jan; 40(1):31-43. PubMed ID: 32794426
[TBL] [Abstract][Full Text] [Related]
59. Antiplasmodial profile of selected compounds from Malaria Box: in vitro evaluation, speed of action and drug combination studies.
de Souza GE; Bueno RV; de Souza JO; Zanini CL; Cruz FC; Oliva G; Guido RVC; Aguiar ACC
Malar J; 2019 Dec; 18(1):447. PubMed ID: 31888654
[TBL] [Abstract][Full Text] [Related]
60. A rational approach to identify inhibitors of Mycobacterium tuberculosis enoyl acyl carrier protein reductase.
Chhabria MT; Parmar KB; Brahmkshatriya PS
Curr Pharm Des; 2013; 19(21):3878-83. PubMed ID: 23477735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
